117 related articles for article (PubMed ID: 25995744)
1. Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells.
Xiong T; Chen X; Wei H; Xiao H
Arch Med Sci; 2015 Apr; 11(2):301-6. PubMed ID: 25995744
[TBL] [Abstract][Full Text] [Related]
2. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
3. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
4. [Reversal of multidrug resistance of the drug resistant human multiple myeloma cell line MOLP-2/R by curcumin and its relation with FA/BRCA pathway].
Xiao H; Zhang KJ; Zuo XL
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):33-7. PubMed ID: 19563033
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R.
Xiao H; Xiao Q; Zhang K; Zuo X; Shrestha UK
Ann Hematol; 2010 Apr; 89(4):399-404. PubMed ID: 19756599
[TBL] [Abstract][Full Text] [Related]
6. Suppression of cell cycle progression by poly(ADP-ribose) polymerase inhibitor PJ34 in neural stem/progenitor cells.
Kurokawa S; Okuda A; Nishizawa Y; Furukawa K; Sumihiro A; Nakaji Y; Tanaka S; Takehashi M
Biochem Biophys Res Commun; 2019 Feb; 510(1):59-64. PubMed ID: 30665718
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
8. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
Liang BY; Xiong M; Ji GB; Zhang EL; Zhang ZY; Dong KS; Chen XP; Huang ZY
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):535-540. PubMed ID: 26223923
[TBL] [Abstract][Full Text] [Related]
9. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
10. Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.
Peremartí J; Ramos F; Marcos R; Hernández A
Toxicol Sci; 2014 Nov; 142(1):93-104. PubMed ID: 25092648
[TBL] [Abstract][Full Text] [Related]
11. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
Teng F; Beray-Berthat V; Coqueran B; Lesbats C; Kuntz M; Palmier B; Garraud M; Bedfert C; Slane N; Bérézowski V; Szeremeta F; Hachani J; Scherman D; Plotkine M; Doan BT; Marchand-Leroux C; Margaill I
Exp Neurol; 2013 Oct; 248():416-28. PubMed ID: 23876515
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.
Wang Z; Li Y; Lv S; Tian Y
J Int Med Res; 2013 Oct; 41(5):1577-85. PubMed ID: 24097829
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
14. [Antiproliferative effect of curcumin combined with cyclophosmide on the growth of human lymphoma cell line HT/CTX with drug resistance and its relation with FA/BRCA pathway].
Xiao H; Zhang KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):804-8. PubMed ID: 18718065
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.
Scott GS; Kean RB; Mikheeva T; Fabis MJ; Mabley JG; Szabó C; Hooper DC
J Pharmacol Exp Ther; 2004 Sep; 310(3):1053-61. PubMed ID: 15159442
[TBL] [Abstract][Full Text] [Related]
16. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
[TBL] [Abstract][Full Text] [Related]
17. Silencing of fanconi anemia complementation group f exhibits potent chemosensitization of mitomycin C activity in breast cancer cells.
Yu J; Zhao L; Li Y; Li N; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
J Breast Cancer; 2013 Sep; 16(3):291-9. PubMed ID: 24155758
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Haddad M; Beray-Berthat V; Coqueran B; Plotkine M; Marchand-Leroux C; Margaill I
Fundam Clin Pharmacol; 2013 Aug; 27(4):393-401. PubMed ID: 22436003
[TBL] [Abstract][Full Text] [Related]
19. Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice.
Haddad M; Beray-Berthat V; Coqueran B; Palmier B; Szabo C; Plotkine M; Margaill I
Eur J Pharmacol; 2008 Jun; 588(1):52-7. PubMed ID: 18468597
[TBL] [Abstract][Full Text] [Related]
20. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
